论文部分内容阅读
目的:探讨不同剂量瑞舒伐他汀对急性动脉硬化脑梗死(ACI)病人外周血淋巴细胞OX40L及血清OX40L和hs-CRP水平的影响。方法:选择40名动脉硬化性脑梗死病人,随机分为瑞舒伐他汀20 mg治疗组(A组)和瑞舒伐他汀10 mg治疗组(B组),应用QRT-PCR及酶联免疫吸附试验(ELISA)法分别检测外周血淋巴细胞OX40L及血清OX40L和hs-CRP的水平。结果:A组与B组外周血淋巴细胞OX40L下降幅度比较(P<0.01)及血清sOX40L和CRP水平治疗后有明显降低(P<0.05),A组与B组比较A组降低更加明显,有统计学意义。结论:动脉硬化性脑梗死病人急性期服用瑞舒伐他汀20 mg能更明显的降低患者外周血淋巴细胞OX40L及血清OX40L和CRP的水平,提示动脉粥样硬化性脑梗死病人早期服用较大剂量的他汀药物治疗效果可能更好。
Objective: To investigate the effect of different doses of rosuvastatin on the levels of OX40L, serum OX40L and hs-CRP in peripheral blood lymphocytes in patients with acute cerebral infarction (ACI). Methods: Forty patients with arteriosclerotic cerebral infarction were randomly divided into two groups: rosuvastatin 20 mg (group A) and rosuvastatin 10 mg (group B). QRT-PCR and enzyme linked immunosorbent assay The levels of OX40L, serum OX40L and hs-CRP in peripheral blood lymphocytes were detected by ELISA. Results: The decrease of OX40L in group A and group B was significantly lower than that in group B (P <0.01) and the level of sOX40L and CRP in group A was significantly lower than that of group B (P <0.05) Statistical significance. Conclusion: The acute phase of arteriosclerosis infarction patients taking rosuvastatin 20 mg can significantly reduce the levels of OX40L and serum OX40L and CRP in patients with peripheral blood lymphocytes, suggesting that early patients taking atherosclerosis cerebral infarction larger doses The statin treatment may be better.